• Amyloid plaques and neurofibrillary tangles in a mouse brain before and after treatment with CLR01
  • Insulin microcrystals in the absence (A) or presence (B) of CLR01
  • Aβ42 fibrils and oligomers (inset) visualized by electron microscopy
  • Neurons (NeuN) and astrocytes (GFAP) in a tauopathy mouse brain
  • Dendritic spines depleted by Aβ42 and rescued by CLR01
  • Time-dependent change in the circular dichroism spectrum of Aβ during aggregation
  • Aβ40 fibrils and oligomers (inset) visualized by electron microscopy
  • Islet amyloid polypeptide fibrils and oligomers (inset) visualized by electron microscopy

Gal Bitan, Ph.D.
Professor of Neurology
David Geffen School of Medicine at UCLA

Announcement: Following the workshop "Strategies and tools for modulating pathologic protein self-assembly", which took place on March 21-22, 2019, in Porto, Portugal, manuscripts are still accepted for consideration of publication in a Research Topic published by Frontiers in Molecular Neuroscience. Participation in the workshop is not a condition for publishing in the Research Topic. If you are interested in submitting a manuscript, contact Dr. Bitan.



Our main research focus is the abnormal self-association of proteins into toxic oligomers, aggregates, and amyloid fibrils and the involvement of these aberrant protein assemblies in human diseases. We study the molecular interactions involved in these processes and explore novel tools to inhibit the formation of the toxic assemblies.

Abnormal protein oligomerization and aggregation cause, or are involved in, over 50 diseases called amyloidoses or proteinopathies. Of this large family of diseases, we study mainly Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Another focus of our lab is the analysis of biomarkers that can improve the diagnosis and facilitate drug development for these diseases.

One of our major projects is the development of "Molecular Tweezers" as novel drug candidates for proteinopathies. We are leading a project called Breakthrough Treatment for Degenerative Diseases (www.BTDD.org) that involves collaboration with multiple laboratories at UCLA and around the world.